| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Nutriband Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.25 |
| 52 Week High | US$5.80 |
| 52 Week Low | US$1.70 |
| Beta | 0.55 |
| 11 Month Change | 14.63% |
| 3 Month Change | 18.24% |
| 1 Year Change | 70.45% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9WV | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 9.8% | -7.0% | -0.1% |
| 1Y | 70.5% | -19.7% | 2.4% |
Return vs Industry: 9WV exceeded the German Pharmaceuticals industry which returned -18.5% over the past year.
Return vs Market: 9WV exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| 9WV volatility | |
|---|---|
| 9WV Average Weekly Movement | 18.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 9WV's share price has been volatile over the past 3 months.
Volatility Over Time: 9WV's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Gareth Sheridan | www.nutriband.com |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
Nutriband Inc. Fundamentals Summary
| 9WV fundamental statistics | |
|---|---|
| Market cap | €55.50m |
| Earnings (TTM) | -€5.93m |
| Revenue (TTM) | €1.88m |
32.8x
P/S Ratio-10.4x
P/E RatioIs 9WV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9WV income statement (TTM) | |
|---|---|
| Revenue | US$2.02m |
| Cost of Revenue | US$1.21m |
| Gross Profit | US$804.61k |
| Other Expenses | US$7.17m |
| Earnings | -US$6.37m |
Last Reported Earnings
Apr 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 39.89% |
| Net Profit Margin | -315.74% |
| Debt/Equity Ratio | 3.8% |
How did 9WV perform over the long term?
See historical performance and comparison